These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23977426)

  • 21. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful chimeric antigen receptor T cell therapy in a case of primary testicular diffuse large-B-cell lymphoma with central nervous system progression.
    Ping N; Qu C; Bai L; Kang L; Chen X; Wu Q; Xia F; Yu L; Yao H; Wu D; Jin Z
    Leuk Lymphoma; 2019 Nov; 60(11):2814-2816. PubMed ID: 31088197
    [No Abstract]   [Full Text] [Related]  

  • 23. Novel diagnostic and therapeutic approaches to malignant glioma.
    Weller M
    Swiss Med Wkly; 2011; 141():w13210. PubMed ID: 21607882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme.
    Bregy A; Wong TM; Shah AH; Goldberg JM; Komotar RJ
    Cancer Treat Rev; 2013 Dec; 39(8):891-907. PubMed ID: 23790634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extraneural metastases in glioblastoma patients: two cases with YKL-40-positive glioblastomas and a meta-analysis of the literature.
    Anghileri E; Castiglione M; Nunziata R; Boffano C; Nazzi V; Acerbi F; Finocchiaro G; Eoli M
    Neurosurg Rev; 2016 Jan; 39(1):37-45; discussion 45-6. PubMed ID: 26212701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glioblastoma multiforme: novel therapeutic targets.
    Muir M; Gopakumar S; Traylor J; Lee S; Rao G
    Expert Opin Ther Targets; 2020 Jul; 24(7):605-614. PubMed ID: 32394767
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Challenges in clinical design of immunotherapy trials for malignant glioma.
    Rolle CE; Sengupta S; Lesniak MS
    Neurosurg Clin N Am; 2010 Jan; 21(1):201-14. PubMed ID: 19944979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
    Desland FA; Hormigo A
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity.
    Zhu H; You Y; Shen Z; Shi L
    Pathol Oncol Res; 2020 Oct; 26(4):2135-2141. PubMed ID: 31989402
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy.
    Strik H; Deininger M; Streffer J; Grote E; Wickboldt J; Dichgans J; Weller M; Meyermann R
    J Neurol Neurosurg Psychiatry; 1999 Dec; 67(6):763-8. PubMed ID: 10567494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bioinformatic profiling identifies an immune-related risk signature for glioblastoma.
    Cheng W; Ren X; Zhang C; Cai J; Liu Y; Han S; Wu A
    Neurology; 2016 Jun; 86(24):2226-34. PubMed ID: 27225222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statistical pattern analysis of gene expression profiles for glioblastoma tissues and cell lines.
    Hess KR; Fuller GN; Rhee CH; Zhang W
    Int J Mol Med; 2001 Aug; 8(2):183-8. PubMed ID: 11445872
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms.
    Berkman RA; Merrill MJ; Reinhold WC; Monacci WT; Saxena A; Clark WC; Robertson JT; Ali IU; Oldfield EH
    J Clin Invest; 1993 Jan; 91(1):153-9. PubMed ID: 8380810
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different molecular patterns in glioblastoma multiforme subtypes upon recurrence.
    Martinez R; Rohde V; Schackert G
    J Neurooncol; 2010 Feb; 96(3):321-9. PubMed ID: 19644652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.
    Batich KA; Swartz AM; Sampson JH
    Expert Opin Biol Ther; 2015 Jan; 15(1):79-94. PubMed ID: 25327832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Updates On Chimeric Antigen Receptor-Mediated Glioblastoma Immunotherapy.
    Mao G; Sampath P; Sengupta S
    R I Med J (2013); 2017 Jun; 100(6):39-42. PubMed ID: 28564668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic and signaling pathway alterations in glioblastoma: relevance to novel targeted therapies.
    Rao RD; Uhm JH; Krishnan S; James CD
    Front Biosci; 2003 May; 8():e270-80. PubMed ID: 12700121
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report.
    Liau LM; Black KL; Martin NA; Sykes SN; Bronstein JM; Jouben-Steele L; Mischel PS; Belldegrun A; Cloughesy TF
    Neurosurg Focus; 2000 Dec; 9(6):e8. PubMed ID: 16817691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disentangling the therapeutic tactics in GBM: From bench to bedside and beyond.
    Daisy Precilla S; Kuduvalli SS; Thirugnanasambandhar Sivasubramanian A
    Cell Biol Int; 2021 Jan; 45(1):18-53. PubMed ID: 33049091
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent Advances in Immune Cell Therapy for Glioblastoma.
    Kang X; Zheng Y; Hong W; Chen X; Li H; Huang B; Huang Z; Tang H; Geng W
    Front Immunol; 2020; 11():544563. PubMed ID: 33193310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.